D. Christoulas
About
D. Christoulas is a scholar working on Oncology, Hematology and Molecular Biology.
According to data from OpenAlex, D. Christoulas has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 16 papers in Hematology and 10 papers in Molecular Biology. Recurrent topics in D. Christoulas's work include Multiple Myeloma Research and Treatments (13 papers), Bone health and treatments (10 papers) and Peptidase Inhibition and Analysis (6 papers). D. Christoulas is often cited by papers focused on Multiple Myeloma Research and Treatments (13 papers), Bone health and treatments (10 papers) and Peptidase Inhibition and Analysis (6 papers). D. Christoulas collaborates with scholars based in Greece, United States and United Kingdom. D. Christoulas's co-authors include Evangelos Terpos, Meletios Α. Dimopoulos, Efstathios Kastritis, Μαρία Ρούσσου, Magdalini Migkou, Dimitra Gika, Evangelos Eleftherakis-Papaiakovou, Christina Bamia, Aristotle Bamias and Ioannis Melakopoulos and has published in prestigious journals such as Annals of Oncology, Bone and Leukemia.
In The Last Decade
D. Christoulas
21 papers receiving 1.1k citations
Peers
D. Christoulas
Evgenia Verrou Greece
Kamel Laribi France
Delia Cangini Italy
G. Kettner Germany
Antonietta Falcone Italy
Christos Kiamouris Greece
Eurydiki Michalis Greece
Abderrahmane Laadem United States
Eva Löfvenberg Sweden
Andrea Kündgen Germany
Citations per year, relative to D. Christoulas D. Christoulas (= 1×)
peers
Evgenia Verrou
Countries citing papers authored by D. Christoulas
Since
Specialization
Citations
This map shows the geographic impact of D. Christoulas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Christoulas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Christoulas more than expected).
Fields of papers citing papers by D. Christoulas
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by D. Christoulas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Christoulas. The network helps show where D. Christoulas may publish in the future.
Co-authorship network of co-authors of D. Christoulas
This figure shows the co-authorship network connecting the top 25 collaborators of D. Christoulas. A scholar is included among the top collaborators of D. Christoulas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Christoulas. D. Christoulas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Eleutherakis‐Papaiakovou, Evangelos, Meletios Α. Dimopoulos, Efstathios Kastritis, et al.. (2017). Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis. Bone Marrow Transplantation. 52(11). 1537–1542.
2.
Terpos, Evangelos, D. Christoulas, Maria Gavriatopoulou, & Meletios Α. Dimopoulos. (2017). Mechanisms of bone destruction in multiple myeloma. European Journal of Cancer Care. 26(6). e12761–e12761.
3.
Anagnostis, Panagiotis, Sofia Vakalopoulou, D. Christoulas, et al.. (2017). The role of sclerostin/dickkopf‐1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross‐sectional study. Haemophilia. 24(2). 316–322.
4.
Terpos, Evangelos, Magdalini Migkou, D. Christoulas, et al.. (2016). Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. Blood Cancer Journal. 6(5). e428–e428.
5.
Terpos, Evangelos, D. Christoulas, Efstathios Kastritis, et al.. (2016). High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma. Blood Cancer Journal. 6(10). e482–e482.
6.
Terpos, Evangelos, D. Christoulas, Efstathios Kastritis, et al.. (2015). Sclerostin Remains Elevated Even in the Plateau Phase of Myeloma Patients: Implications into the Pathogenesis of Osteoblast Dysfunction of Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 15. e229–e229.
7.
Terpos, Evangelos, D. Christoulas, Efstathios Kastritis, et al.. (2013). VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. Leukemia. 28(4). 928–934.
8.
Terpos, Evangelos, Bouchra Asli, D. Christoulas, et al.. (2012). Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. Haematologica. 97(11). 1699–1703.
9.
Terpos, Evangelos, Efstathios Kastritis, D. Christoulas, et al.. (2012). Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Annals of Oncology. 23(10). 2681–2686.
10.
Voskaridou, Ersi, D. Christoulas, Cornelia Bratengeier, et al.. (2012). High Circulating Sclerostin is Present in Patients with Thalassemia-associated Osteoporosis and Correlates with Bone Mineral Density. Hormone and Metabolic Research. 44(12). 909–913.
11.
Anargyrou, Konstantinos, T. P. Vassilakopoulos, Konstantinos Tsionos, et al.. (2011). Low bone mineral density and high bone turnover in patients with non-Hodgkin's lymphoma (NHL) who receive frontline therapy: Results of a multicenter prospective study. Bone. 48. S254–S255.
12.
Dimopoulos, Meletios Α., Efstathios Kastritis, D. Christoulas, et al.. (2010). Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 24(10). 1769–1778.
13.
Terpos, Evangelos, Eirini Katodritou, Efstathios Kastritis, et al.. (2009). Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica. 94(3). 372–379.
14.
Voskaridou, Ersi, et al.. (2009). Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica. 94(5). 725–728.
15.
Voskaridou, Ersi, et al.. (2009). Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica. 94(5). 725–728.
16.
Kastritis, Efstathios, Konstantinos Zervas, Argiris Symeonidis, et al.. (2009). Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia. 23(6). 1152–1157.
17.
Dimopoulos, Meletios Α., Efstathios Kastritis, Christina Bamia, et al.. (2008). Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology. 20(1). 117–120.
18.
Anargyrou, Konstantinos, Evangelos Terpos, T. P. Vassilakopoulos, et al.. (2008). Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica. 93(3). 451–454.
19.
Terpos, Evangelos, Efstathios Kastritis, Μαρία Ρούσσου, et al.. (2008). The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia. 22(12). 2247–2256.
20.
Voskaridou, Ersi, et al.. (2007). Pulmonary hypertension in patients with sickle cell/ thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica. 92(6). 738–743.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Evgenia Verrou Breakdown of academic impact, for papers by Kamel Laribi Breakdown of academic impact, for papers by Delia Cangini Breakdown of academic impact, for papers by G. Kettner Breakdown of academic impact, for papers by Antonietta Falcone Breakdown of academic impact, for papers by Christos Kiamouris Breakdown of academic impact, for papers by Eurydiki Michalis Breakdown of academic impact, for papers by Abderrahmane Laadem Breakdown of academic impact, for papers by Eva Löfvenberg Breakdown of academic impact, for papers by Andrea Kündgen